Mergers & Acquisitions
Swedish biotech acquires Nurel Therapeutics
Published in Gene Therapy Weekly, December 22nd, 2005
The merger is subject to approval by the board of directors of each company and their respective shareholders. The Diamyd Medical board of directors plans to request shareholder approval for the merger at the annual general shareholders meeting on December 12, 2005.
The merger will create a global biotechnology company focusing on the treatment of diabetes and its complications including chronic pain and neuropathy.
Diamyd Medical has valued Nurel at US$1.5 million....
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
Source: Gene Therapy Weekly (2005-12-22)
More Articles from Gene Therapy Weekly
- Biomedical Engineering
Chimeric antibody is expressed in mammalian cells using a dicistronic expression vector - DNA Research
Quercetin inhibition of iNOS gene expression is mediated by the inhibition of microglial factors - DNA Research
Simple cationic peptide motif allows delivery of antisense peptide nucleic acid - Gene Research
Antibiotic marker cassettes for gene disruption and marker switching constructed - Transplantation Medicine
Actin cytoskeleton regulator depletion suppresses cardiac allograft rejection - Allergy & Immunology
Promoter polymorphisms are associated with increased risk of atopic dermatitis - More from this issue of Gene Therapy Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
